Phase II study of 4-demethoxydaunorubicin in previously untreated extensive disease non-small cell lung cancer

Fifteen patients with previously untreated extensive non-small cell lung cancer (E-NSCLC) were treated with oral 4-demethoxydaunorubicin (4-DMDR) at the dose of 10 mg/m2/day x 5 days every 3 weeks with routine administration of antiemetic drugs. They received a median of two courses of treatment wit...

Ausführliche Beschreibung